ISCHEMIA trial, DAPA-HF, and valsartan recall: AHA Special

In this special meeting edition of the Cardiocast, MDedge Cardiology editor Catherine Hackett is joined by MDedge reporters Mitchel L. Zoler, Bruce Jancin, and Richard Mark Kirkner. 

The MDedge cardiology team reviews three big stories from the 2019 annual scientific sessions of the American Heart Association in Philadelphia. 

* * * 

Help us make this podcast better! Please take this short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019

* * *

ISCHEMIA trial hailed as practice changing

The results of the ISCHEMIA trial were emphatically declared practice changing by interventional cardiologists and noninterventionalists alike at the AHA meeting. 

Bruce Jancin discusses the story.

DAPA-HF: Dapagliflozin's HFrRF efficacy confirmed in nondiabetes

The results in nondiabetics from the practice-changing DAPA-HF trial gives clinicians strong evidence that the diabetes drug dapagliflozin is equally effective at reducing cardiovascular death and acute exacerbations in heart failure patients regardless of diabetes status. 

Mitchel L. Zoler discusses this report. 

Weakness exposed in valsartan recall

ED visits for hypertension in the month after the 2018 recall spiked 55%. The 2018 recall of generic forms of the antihypertensive drug valsartan exposed weaknesses in the recall systems for generics in both the U.S. and Canada that caused many patients who were on the drug to fall through the cracks. 

Richard Mark Kirkner goes deeper into this story. 

*  *  *  

For full coverage of AHA 2019 visit MDedge Cardiology

For more MDedge Podcasts, go to mdedge.com/podcasts

Email the show: [e-mail]

Interact with us on Twitter: @MDedgeCardio